Document

展示99.1

IQVIAは2024年第3四半期の業績を報告

そして、インベスターデイを発表しました

•売上高は$389600万

•当期純利益は28500万ドル、調整後のEBITDAは93900万ドルです

•希薄化後調整後1株当たり$1.55、調整後1株当たり$2.84

•R＆Dソリューションズの四半期予約額は23億ドルであり、直近12か月間の予約総額は104億ドルで、直近12か月間のブック・トゥ・ビル比率は1.22倍です。

•研究開発ソリューションの受注残高は310億ドルで、前年比8.0パーセント増加しました。

•TASの売上高は155400万ドルで、前年同期比8.6％増

•Operating Cash Flowが72100万ドルになり、これにより年初からのOperating Cash Flowは183100万ドルに達し、前年比31パーセント増加しました。

•フリーキャッシュフローは57100万ドルで、累計フリーキャッシュフローは139300万ドルで、前年比49パーセント増加しました。

•2024年度のガイダンスは、売上高が1535000万ドルから1540000万ドル、調整後のEBITDAが367500万ドルから370000万ドル、調整後の希薄化後１株利益が11.10ドルから11.20ドルの間に更新されました

•2024年12月10日に開催されるインベスターデイ

リサーチ・トライアングル・パーク、N.C. – （ビジネスワイヤー） – 2024年10月31日 – アイキューヴィア・ホールディングス（IQVIA）（nyse:IQV）、世界をリードするクリニカルリサーチサービス、商業洞察、医療インテリジェンスのグローバルプロバイダーであるアイキュヴィアは、生命科学およびヘルスケア業界向けに2024年9月30日に終了した四半期の財務結果を報告しました。

2024年第三四半期の業績結果

2023年第3四半期の売上高は$389600万で、報告ベースでは4.3％増、為替レートを一定にした場合は4.2％増となりました。テクノロジー＆アナリティクスソリューション（TAS）の売上高は$155400万で、報告ベースでは8.6％増、為替レートを一定にした場合は8.2％増となりました。リサーチ＆デベロップメントソリューション（R＆DS）の売上高は$216200万で、報告ベースでは1.9％増、為替レートを一定にした場合は2.0％増となりました。また、R＆DSの売上高はパススルーの影響を除くと、報告ベースで3.2％増加しました。契約型営業＆医療ソリューション（CSMS）の売上高は$18000万で、報告ベースでは1.6％減、為替レートを一定にした場合は1.1％減少しました。

2024年9月30日現在、R&D契約残高（経費の払い戻しを含む）は310億ドルで、前年比8.0％増、定常通貨ベースでは6.7％増加しています。会社はこの契約残高のうち約78億ドルが次の12か月で売上高に換算されることを予想しています。第3四半期の受注残高売上高比率は1.06倍であり、大規模なプログラムの中止による影響を含めた数字です（この大規模なプログラムの中止を除くと1.22倍です）。2024年9月30日までの12か月間の受注残高売上高比率は1.22倍です。

第3四半期のGAAP当期純利益は2億8500万ドルで、GAAP希薄化後1株当たり利益は1.55ドルでした。調整後のEBITDAは9億3900万ドルで、前年比5.7パーセント増加しました。調整後の当期純利益は5億2300万ドルで、調整後の希薄化後1株当たり利益はそれぞれ2.84ドルで、それぞれ13.2パーセント、14.1パーセント増加しました。

2024年度の累計運営結果

2024年の第1四半期から第3四半期までの売上高は1144700万ドルであり、報告された基準では3.0パーセント増加し、一定の為替レートでは3.5パーセント増加しました。これは2023年の第1四半期から第3四半期までと比較しています。TASの売上高は450200万ドルであり、報告された基準では3.9パーセント成長し、一定の為替レートでは4.3パーセント成長しました。R&Dの売上高は640400万ドルであり、報告された基準では2.6パーセント増加し、一定の為替レートでは3.0パーセント増加しました。CSMSの売上高は54100万ドルであり、報告時には前年同期比で横ばいであり、一定の為替レートでは3.0パーセント増加しました。

GAAP当期純利益は93600万ドルで、GAAP希薄化後1株当たり利益は5.08ドルでした。調整後EBITDAは268800万ドルでした。調整後当期純利益は147800万ドルで、調整後希薄化後1株当たり利益は8.02ドルでした。

財務状況

2024年9月30日時点で、現金及び現金同等物は$157,200万で、負債は$1,351,200万で、純負債は$1194000万です。IQVIAの純負債比率は、過去12ヶ月の調整後EBITDAに対して3.27倍です。第3四半期のオペレーティングキャッシュフローは$72,100万で、フリーキャッシュフローは$57,100万でした。

株の自己買い戻し

2024年第3四半期に、会社は普通株式の200百万ドルを買い戻しました。 IQVIAは2024年9月30日時点で2億1630万ドルの株式買い戻し権限を残していました。

2024年度の年間ガイダンス

会社は2024年通年の見通しを更新しています顧客関連の短期的な物流上の課題に起因して、2つの急速なメガトライアルの遅延を反映するためにガイダンスを調整しました。これらのトライアルは2025年下半期に本格化する見込みです。その結果、2024年の売上高は$1535000万と$1540000万の間になる見込みであり、調整後のEBITDAは$367500万から$370000万の間、調整後の希薄化後1株利益は$11.10から$11.20の間になる見込みです。

全セクターの財務ガイダンスは、2024年10月30日時点の外国為替レートが予測期間において有効であると想定しています。

IQVIAの会長兼CEO、Ari Bousbibは、「IQVIAは強力な第3四半期の業績を報告しました。利益率が拡大し、強力なフリーキャッシュフロー、および二桁の調整後希薄化後eps成長を達成しました。予想通り、tas売上高成長は四半期に加速しました。実際、売上高成長は前年同期比で8％を超え、このセグメントの持続的な回復に対する私たちの信頼を裏付けました。r＆ds売上高成長は私たちの期待を満たし、ただし、1つの大規模なプログラムのキャンセルと2つのメガトライアルの遅延の合併効果により、当面の見通しに影響を受けています。 R＆DSの事業基盤は確固としており、rpfフロー、資格を得たパイプラインの成長、バックログの成長、およびバックログからの次の12か月間の収益などの先行指標は健全な状態を維持しています。

インベスターデイ

IQVIAは2024年12月10日（火曜日）、North CarolinaのInnovation Park本社でインベスターデイを開催します。経営陣はビジネスの最新情報を提供し、IQVIAのシニア幹部チームからのプレゼンテーションが午前10時30分（米国東部時間）に開始し、およそ午後1時（米国東部時間）に終了します。プレゼンテーション後、参加者は製品デモンストレーションや研究施設のガイドツアーに参加する機会があります。イベントの詳細は、IQVIAのインベスターリレーションズウェブサイトhttp://ir.iqvia.comで入手できます。

Webcast＆Conference Callの詳細

本日午前9時（東部時間）に、IQVIAは2024年第3四半期の業績や2024年第4四半期および年間業績について議論するための会議コールを開催します。イベントを聴くおよびプレゼンテーションスライドをウェブキャストで表示するには、IQVIA投資家向けウェブサイト（http://ir.iqvia.com）から参加してください。会議コールに参加するには、関心をお持ちの方はこのリンクをクリックして事前に登録する必要があります。登録後、参加者は、会議コールに参加する方法に関する詳細、ダイヤルイン番号、ユニークなパスコード、登録IDが記載された確認メールを受け取ります。ライブイベント時、登録済みの参加者は確認メールで提供された情報を使用してコールに接続し、直接会議コールに移動されます。

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI™, advanced analytics, the latest technologies and extensive domain expertise. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

Cautionary Statements Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, our full-year 2024 guidance. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “assume,” “anticipate,” “intend,” “plan,” “forecast,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from our expectations due to a number of factors, including, but not limited to, the following: business disruptions caused by natural disasters, pandemics such as the COVID-19 (coronavirus) outbreak, including any variants, and the public health policy responses to the outbreak, and international conflicts or other disruptions outside of our control such as the current situation in Ukraine and Russia; most of our contracts may be terminated on short notice, and we may lose or experience delays with large client contracts or be unable to enter into new contracts; the market for our services may not grow as we expect; we may be unable to successfully develop and market new services or enter new markets; imposition of restrictions on our use of data by data suppliers or their refusal to license data to us; any failure by us to comply with contractual, regulatory or ethical requirements under our contracts, including current or future changes to data protection and privacy laws; breaches or misuse of our or our outsourcing partners’ security or communications systems; failure to meet our productivity or business transformation objectives; failure to successfully invest in growth opportunities; our ability to protect our intellectual property rights and our susceptibility to claims by others that we are infringing on their intellectual property rights; the expiration or inability to acquire third party licenses for technology or intellectual property; any failure by us to accurately and timely price and formulate cost estimates for contracts, or to document change orders; hardware and software failures, delays in the operation of our computer and communications systems or the failure to implement system enhancements; the rate at which our backlog converts to revenue; our ability to acquire, develop and implement technology necessary for our business; consolidation in the industries in which our clients operate; risks related to client or therapeutic concentration; government regulators or our customers may limit the number or scope of indications for medicines and treatments or withdraw products from the market, and government regulators may impose new regulatory requirements or may adopt new regulations affecting the biopharmaceutical industry; the risks associated with operating on a global basis, including currency or exchange rate fluctuations and legal compliance, including anti-corruption laws; risks related to changes in accounting standards; general economic conditions in the markets in which we operate, including financial market conditions, inflation, and risks related to sales to government entities; the impact of changes in tax laws and regulations; and our ability to successfully integrate, and achieve expected benefits from, our acquired businesses. For a further discussion of the risks relating to our business, see the “Risk Factors” in our annual report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (the "SEC"), as such factors may be amended or updated from time to time in our subsequent periodic and other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC. We assume no obligation to update any such forward-looking statement after the date of this release, whether as a result of new information, future developments or otherwise.

Note on Non-GAAP Financial Measures

This release includes information based on financial measures that are not recognized under generally accepted accounting principles in the United States ("GAAP"), such as Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted Earnings per Share, Gross Leverage Ratio, Net Leverage Ratio and Free Cash Flow. Non-GAAP financial measures are presented only as a supplement to the company’s financial statements based on GAAP. Non-GAAP financial information is provided to enhance understanding of the company’s financial performance, but none of these non-GAAP financial measures are recognized terms under GAAP, and non-GAAP measures should not be considered in isolation from, or as a substitute analysis for, the company’s results of operations as determined in accordance with GAAP. The company uses non-GAAP measures in its operational and financial decision making, and believes that it is useful to exclude certain items in order to focus on what it regards to be a more meaningful indicator of the underlying operating performance of the business. For example, the company excludes all the amortization of intangible assets associated with acquired customer relationships and backlog, databases, non-compete agreements, trademarks and trade names from non-GAAP expense and income measures as such amounts can be significantly impacted by the timing and size of acquisitions. Although we exclude amortization of acquired intangible assets from our non-GAAP expenses, we believe that it is important for investors to understand that revenue generated from such intangibles is included within revenue in determining net income. As a result, internal management reports feature non-GAAP measures which are also used to prepare strategic plans and annual budgets and review management compensation. The company also believes that investors may find non-GAAP financial measures useful for the same reasons, although investors are cautioned that non-GAAP financial measures are not a substitute for GAAP disclosures.

The non-GAAP financial measures are not presented in accordance with GAAP. Please refer to the schedules attached to this release for reconciliations of non-GAAP financial measures contained herein to the most directly comparable GAAP measures. Our full-year 2024 guidance measures (other than revenue) are provided on a non-GAAP basis without a reconciliation to the most directly comparable GAAP measure because the company is unable to predict with a reasonable degree of certainty certain items contained in the GAAP measures without unreasonable efforts. For the same reasons, the company is unable to address the probable significance of the unavailable information. Such items include, but are not limited to, acquisition related expenses, restructuring and related expenses, stock-based compensation and other items not reflective of the company's ongoing operations.

Non-GAAP measures are frequently used by securities analysts, investors and other interested parties in their evaluation of companies comparable to the company, many of which present non-GAAP measures when reporting their results. Non-GAAP measures have limitations as an analytical tool. They are not presentations made in accordance with GAAP, are not measures of financial condition or liquidity and should not be considered as an alternative to profit or loss for the period determined in accordance with GAAP or operating cash flows determined in accordance with GAAP. Non-GAAP measures are not necessarily comparable to similarly titled measures used by other companies. As a result, you should not consider such performance measures in isolation from, or as a substitute analysis for, the company’s results of operations as determined in accordance with GAAP.

IQVIAFIN

# # #

Table 1

IQVIA HOLDINGS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(preliminary and unaudited)


	Three Months Ended September 30,				Nine Months Ended September 30,
(in millions, except per share data)	2024		2023		2024		2023
Revenues	$	3,896	$	3,736	$	11,447	$	11,116
Cost of revenues, exclusive of depreciation and amortization	2,518		2,426		7,450		7,267
Selling, general and administrative expenses	522		502		1,539		1,497
Depreciation and amortization	278		297		811		809
Restructuring costs	28		30		71		67
Income from operations	550		481		1,576		1,476
Interest income	(13)		(14)		(36)		(24)
Interest expense	170		181		499		491

Other expense (income), net	44		(35)		(12)		(77)
Income before income taxes and equity in earnings of unconsolidated affiliates	349		349		1,125		1,086
Income tax expense	65		51		189		203
Income before equity in earnings of unconsolidated affiliates	284		298		936		883
Equity in earnings of unconsolidated affiliates	1		5		—		6
Net income	$	285	$	303	$	936	$	889
Earnings per share attributable to common stockholders:
Basic	$	1.57	$	1.66	$	5.14	$	4.82
Diluted	$	1.55	$	1.63	$	5.08	$	4.76
Weighted average common shares outstanding:
Basic	182.1		182.9		182.1		184.4
Diluted	184.2		185.5		184.3		186.9

Table 2

IQVIA HOLDINGS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(preliminary and unaudited)


(in millions, except per share data)	September 30, 2024		December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents	$	1,572	$	1,376
Trade accounts receivable and unbilled services, net	3,196		3,381
Prepaid expenses	195		141
Income taxes receivable	54		32
Investments in debt, equity and other securities	140		120
Other current assets and receivables	475		546
Total current assets	5,632		5,596
Property and equipment, net	513		523
Operating lease right-of-use assets	259		296
Investments in debt, equity and other securities	117		105
Investments in unconsolidated affiliates	203		134
Goodwill	15,091		14,567
Other identifiable intangibles, net	4,734		4,839
Deferred income taxes	164		166
Deposits and other assets, net	467		455
Total assets	$	27,180	$	26,681
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	3,434	$	3,564
Unearned income	1,824		1,799
Income taxes payable	161		116
Current portion of long-term debt	1,219		718
Other current liabilities	354		294
Total current liabilities	6,992		6,491
Long-term debt, less current portion	12,293		12,955
Deferred income taxes	128		202
Operating lease liabilities	188		223
Other liabilities	612		698
Total liabilities	20,213		20,569
Commitments and contingencies
Stockholders’ equity:
Common stock and additional paid-in capital, 400.0 shares authorized as of September 30, 2024 and December 31, 2023, $0.01 par value, 258.1 shares issued and 181.6 shares outstanding as of September 30, 2024; 257.2 shares issued and 181.5 shares outstanding as of December 31, 2023	11,106		11,028
Retained earnings	5,628		4,692
Treasury stock, at cost, 76.5 and 75.7 shares as of September 30, 2024 and December 31, 2023, respectively	(8,941)		(8,741)
Accumulated other comprehensive loss	(826)		(867)
Total stockholders’ equity	6,967		6,112
Total liabilities and stockholders’ equity	$	27,180	$	26,681

Table 3

IQVIA HOLDINGS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(preliminary and unaudited)


	Nine Months Ended September 30,
(in millions)	2024		2023
Operating activities:
Net income	$	936	$	889
Adjustments to reconcile net income to cash provided by operating activities:
Depreciation and amortization	811		809
Amortization of debt issuance costs and discount	16		13
Stock-based compensation	158		172
Earnings from unconsolidated affiliates	—		(6)
Gain on investments, net	(29)		(5)
Benefit from deferred income taxes	(114)		(117)
Changes in operating assets and liabilities:
Change in accounts receivable, unbilled services and unearned income	259		(241)
Change in other operating assets and liabilities	(206)		(112)
Net cash provided by operating activities	1,831		1,402
Investing activities:
Acquisition of property, equipment and software	(438)		(470)
Acquisition of businesses, net of cash acquired	(649)		(869)
Purchases of marketable securities, net	—		(4)
Investments in unconsolidated affiliates, net of payments received	(68)		(16)
Investments in debt and equity securities	(2)		(36)
Proceeds from sale of property, equipment and software	25		—
Other	(2)		4
Net cash used in investing activities	(1,134)		(1,391)
Financing activities:
Proceeds from issuance of debt	—		1,250
Payment of debt issuance costs	—		(19)
Repayment of debt and principal payments on finance leases	(130)		(118)
Proceeds from revolving credit facility	685		2,009
Repayment of revolving credit facility	(785)		(2,184)
Payments related to employee stock incentive plans	(61)		(58)
Repurchase of common stock	(200)		(763)
Contingent consideration and deferred purchase price payments	(12)		(79)
Net cash (used in) provided by financing activities	(503)		38
Effect of foreign currency exchange rate changes on cash	2		(41)
Increase in cash and cash equivalents	196		8
Cash and cash equivalents at beginning of period	1,376		1,216
Cash and cash equivalents at end of period	$	1,572	$	1,224

Table 4

IQVIA HOLDINGS INC. AND SUBSIDIARIES

NET INCOME TO ADJUSTED EBITDA RECONCILIATION

(preliminary and unaudited)


	Three Months Ended September 30,				Nine Months Ended September 30,
(in millions)	2024		2023		2024		2023
Net Income	$	285	$	303	$	936	$	889
Provision for income taxes	65		51		189		203
Depreciation and amortization	278		297		811		809
Interest expense, net	157		167		463		467
Income in unconsolidated affiliates	(1)		(5)		—		(6)


Stock-based compensation	54		47		158		172
Other expense (income), net (1)	56		(40)		11		(92)

Restructuring and related expenses (2)	38		42		99		102
Acquisition related expenses	7		26		21		59
Adjusted EBITDA	$	939	$	888	$	2,688	$	2,603

(1) Reflects certain non-operating income items, revaluations of contingent consideration and certain non-recurring expenses.

(2) Reflects restructuring costs as well as accelerated expenses related to lease exits.

Table 5

IQVIA HOLDINGS INC. AND SUBSIDIARIES

NET INCOME TO ADJUSTED NET INCOME RECONCILIATION

(preliminary and unaudited)


	Three Months Ended September 30,				Nine Months Ended September 30,
(in millions, except per share data)	2024		2023		2024		2023
Net Income	$	285	$	303	$	936	$	889
Provision for income taxes	65		51		189		203
Purchase accounting amortization (1)	139		156		401		411
Income in unconsolidated affiliates	(1)		(5)		—		(6)


Stock-based compensation	54		47		158		172
Other expense (income), net (2)	56		(40)		11		(92)


Restructuring and related expenses (3)	38		42		99		102
Acquisition related expenses	7		26		21		59
Adjusted Pre Tax Income	$	643	$	580	$	1,815	$	1,738
Adjusted tax expense	(120)		(118)		(337)		(360)


Adjusted Net Income	$	523	$	462	$	1,478	$	1,378

Adjusted earnings per share attributable to common stockholders:
Basic	$	2.87	$	2.53	$	8.12	$	7.47
Diluted	$	2.84	$	2.49	$	8.02	$	7.37
Weighted average common shares outstanding:
Basic	182.1		182.9		182.1		184.4
Diluted	184.2		185.5		184.3		186.9

(1) Reflects all the amortization of acquired intangible assets.

(2) Reflects certain non-operating income items, revaluations of contingent consideration and certain non-recurring expenses.

(3) Reflects restructuring costs as well as accelerated expenses related to lease exits.

Table 6

IQVIA HOLDINGS INC. AND SUBSIDIARIES

NET CASH PROVIDED BY OPERATING ACTIVITIES TO FREE CASH FLOW RECONCILIATION

(preliminary and unaudited)



(in millions)	Three Months Ended September 30, 2024		Nine Months Ended September 30, 2024
Net Cash provided by Operating Activities	$	721	$	1,831
Acquisition of property, equipment and software	(150)		(438)
Free Cash Flow	$	571	$	1,393

Table 7

IQVIA HOLDINGS INC. AND SUBSIDIARIES

CALCULATION OF GROSS AND NET LEVERAGE RATIOS

AS OF SEPTEMBER 30, 2024

(preliminary and unaudited)


(in millions)
Gross Debt, net of Unamortized Discount and Debt Issuance Costs, as of September 30, 2024	$	13,512
Net Debt as of September 30, 2024	$	11,940
Adjusted EBITDA for the twelve months ended September 30, 2024	$	3,654
Gross Leverage Ratio (Gross Debt/LTM Adjusted EBITDA)	3.70x
Net Leverage Ratio (Net Debt/LTM Adjusted EBITDA)	3.27x

Contacts:

Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com)

+1.610.244.3020